Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy.

Trial Profile

Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2016

At a glance

  • Drugs Lacosamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2011 Actual patient number is 1005 as reported by ClinicalTrials.gov.
    • 18 Oct 2011 Planned End Date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top